Literature DB >> 17336687

The antiphospholipid syndrome.

Michael J Fischer1, Joyce Rauch, Jerrold S Levine.   

Abstract

The antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the clinical association of antiphospholipid autoantibodies (aPL) with a syndrome of hypercoagulability that can affect any blood vessel, irrespective of type or size. Involvement of larger vessels, such as arteries or veins, manifests in the form of thrombosis or embolism, whereas involvement of smaller vessels, including capillaries, arterioles, and venules, manifests as thrombotic microangiopathy. Virtually any organ in the body, including the kidney, can be affected. Here, we review the basic principles and recent advances in our understanding of APS, and discuss the broad spectrum of renal diseases that have been observed in association with this syndrome. We also discuss the impact that APS may have on pre-existing renal disease as well as current recommendations for treatment of APS.

Entities:  

Mesh:

Year:  2007        PMID: 17336687      PMCID: PMC3440307          DOI: 10.1016/j.semnephrol.2006.09.006

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  30 in total

1.  A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.

Authors:  Mark A Crowther; Jeff S Ginsberg; Jim Julian; Judah Denburg; Jack Hirsh; James Douketis; Carl Laskin; Paul Fortin; David Anderson; Clive Kearon; Ann Clarke; William Geerts; Melissa Forgie; David Green; Lorrie Costantini; Wendy Yacura; Sarah Wilson; Michael Gent; Michael J Kovacs
Journal:  N Engl J Med       Date:  2003-09-18       Impact factor: 91.245

2.  Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.

Authors:  M H Rosove; P M Brewer
Journal:  Ann Intern Med       Date:  1992-08-15       Impact factor: 25.391

3.  Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.

Authors:  Maria G Tektonidou; Flora Sotsiou; Lidia Nakopoulou; Panayiotis G Vlachoyiannopoulos; Haralampos M Moutsopoulos
Journal:  Arthritis Rheum       Date:  2004-08

4.  The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus.

Authors:  Micah T McClain; Melissa R Arbuckle; Latisha D Heinlen; Gregory J Dennis; Jon Roebuck; Mark V Rubertone; John B Harley; Judith A James
Journal:  Arthritis Rheum       Date:  2004-04

5.  Development of autoantibodies before the clinical onset of systemic lupus erythematosus.

Authors:  Melissa R Arbuckle; Micah T McClain; Mark V Rubertone; R Hal Scofield; Gregory J Dennis; Judith A James; John B Harley
Journal:  N Engl J Med       Date:  2003-10-16       Impact factor: 91.245

6.  Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment.

Authors:  R H Derksen; P G de Groot; L Kater; H K Nieuwenhuis
Journal:  Ann Rheum Dis       Date:  1993-09       Impact factor: 19.103

7.  Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis.

Authors:  Gabriella Moroni; Donatella Ventura; Paola Riva; Paola Panzeri; Silvana Quaglini; Giovanni Banfi; Paola Simonini; Rossella Bader; Pier Luigi Meroni; Claudio Ponticelli
Journal:  Am J Kidney Dis       Date:  2004-01       Impact factor: 8.860

8.  Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model.

Authors:  Dardo E Ferrara; Xiaowei Liu; Ricardo G Espinola; Pier Luigi Meroni; Imad Abukhalaf; E Nigel Harris; Silvia S Pierangeli
Journal:  Arthritis Rheum       Date:  2003-11

9.  Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis.

Authors:  K S Ginsburg; M H Liang; L Newcomer; S Z Goldhaber; P H Schur; C H Hennekens; M J Stampfer
Journal:  Ann Intern Med       Date:  1992-12-15       Impact factor: 25.391

10.  The management of thrombosis in the antiphospholipid-antibody syndrome.

Authors:  M A Khamashta; M J Cuadrado; F Mujic; N A Taub; B J Hunt; G R Hughes
Journal:  N Engl J Med       Date:  1995-04-13       Impact factor: 91.245

View more
  16 in total

Review 1.  Future research directions to improve fistula maturation and reduce access failure.

Authors:  Haidi Hu; Sandeep Patel; Jesse J Hanisch; Jeans M Santana; Takuya Hashimoto; Hualong Bai; Tambudzai Kudze; Trenton R Foster; Jianming Guo; Bogdan Yatsula; Janice Tsui; Alan Dardik
Journal:  Semin Vasc Surg       Date:  2016-08-26       Impact factor: 1.000

2.  Catastrophic antiphospholipid syndrome presented with sudden renal failure and history of long-lasting psychosis and hypertension in a 42 years old women.

Authors:  Saeed Mardani; Hamid Nasri
Journal:  J Nephropathol       Date:  2013-04-01

3.  Hypertension and renal failure with right arm pulse weakness in a 65 years old man.

Authors:  Hamid Nasri
Journal:  J Nephropathol       Date:  2012-10-01

Review 4.  The Biology of Hemodialysis Vascular Access Failure.

Authors:  Akshaar Brahmbhatt; Sanjay Misra
Journal:  Semin Intervent Radiol       Date:  2016-03       Impact factor: 1.513

5.  Renal thrombotic microangiopathies/thrombotic thrombocytopenic purpura in a patient with primary Sjögren's syndrome complicated with IgM monoclonal gammopathy of undetermined significance.

Authors:  Tomohiro Koga; Satoshi Yamasaki; Hideki Nakamura; Atsushi Kawakami; Akira Furusu; Takashi Taguchi; Katsumi Eguchi
Journal:  Rheumatol Int       Date:  2010-07-22       Impact factor: 2.631

6.  Recurrent thrombosis prevention with intravenous immunoglobulin and hydroxychloroquine during pregnancy in a patient with history of catastrophic antiphospholipid syndrome and pregnancy loss.

Authors:  Nataliya Mar; Rebecca Kosowicz; Karen Hook
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

7.  Prevalence of anti- beta2GPI antibodies and their isotypes in patients with renal diseases and clinical suspicion of antiphospholipid syndrome.

Authors:  Sabiha Anis; Ejaz Ahmed; Rana Muzaffar
Journal:  J Nephropathol       Date:  2013-07-01

8.  Association of early kidney allograft failure with preformed IgA antibodies to β2-glycoprotein I.

Authors:  Jose M Morales; Jose Angel Martinez-Flores; Manuel Serrano; Maria José Castro; Francisco Javier Alfaro; Florencio García; Miguel Angel Martínez; Amado Andrés; Esther González; Manuel Praga; Estela Paz-Artal; Antonio Serrano
Journal:  J Am Soc Nephrol       Date:  2014-07-28       Impact factor: 10.121

Review 9.  What nephrolopathologists need to know about antiphospholipid syndrome-associated nephropathy: Is it time for formulating a classification for renal morphologic lesions?

Authors:  Muhammed Mubarak; Hamid Nasri
Journal:  J Nephropathol       Date:  2014-01-01

10.  The Pathogenicity of Anti-β2GP1-IgG Autoantibodies Depends on Fc Glycosylation.

Authors:  Christoph Fickentscher; Iryna Magorivska; Christina Janko; Mona Biermann; Rostyslav Bilyy; Cecilia Nalli; Angela Tincani; Veronica Medeghini; Antonella Meini; Falk Nimmerjahn; Georg Schett; Luis E Muñoz; Laura Andreoli; Martin Herrmann
Journal:  J Immunol Res       Date:  2015-06-22       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.